Case 1: RAI-Refractory DTC
Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.
Potential Case Outcomes for 65-Year-Old Man With mCRC
Tanios Bekaii-Saab, MD, FACP, concludes with a discussion of potential outcomes for a 65-year-old patient with stage 4 metastatic colorectal cancer.
Subsequent Lines of Therapy and Non-Chemotherapy Options for mCRC
Dr Bekaii-Saab reviews options for subsequent lines of therapy for metastatic colorectal cancer, including non-chemotherapy options.
Capecitabine/Bevacizumab and Signs of Progression/Recurrence for mCRC
An expert elaborates on the importance of the capecitabine + bevacizumab combination therapy for metastatic colorectal cancer, as well as what signs of progression or recurrence to look for in patients.
First-Line Therapy Options for mCRC
Dr Bekaii-Saab discusses therapy options for first-line treatment of metastatic colorectal cancer.
Overview: A 65-Year-Old Man with Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD, FACP, provides an overview of a case involving a 65-year-old man diagnosed with stage 4 metastatic colorectal cancer.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab
Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.
CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL
Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.
Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy
The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.
An Introduction to DLBCL: Current Approaches and Challenges
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.
Regorafenib Sequencing and the Future of Metastatic Colorectal Cancer Management
John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.
Regorafenib as a Metastatic Colorectal Cancer Therapy Option
Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.
Progression on Metastatic Colorectal Cancer Treatment
A gastrointestinal cancers expert describes monitoring strategies for progression of metastatic colorectal cancer.
Frontline Treatment and Maintenance for Metastatic Colorectal Cancer
Dr Marshall explains the different frontline treatment options for metastatic colorectal cancer, as well as maintenance therapy.
Getting to Know Colorectal Cancer
John Marshall, MD, provides an overview of the colorectal cancer landscape.
Ovarian Cancer: Current Status and Future Directions
Ramez Eskander, MD, summarizes the current status of ovarian cancer treatment and reviews unanswered questions and future directions.
Considerations for Selecting PARP Inhibitor Maintenance Therapy
Dr Ramez Eskander shares his insights on considerations for selecting appropriate PARP inhibitor therapy for patients based on molecular testing and other factors.
PARP Inhibitors in Advanced Ovarian Cancer: Mechanism of Action and Tolerability
An expert in ovarian cancer discusses the mechanism of action of PARP inhibitors in treating advanced ovarian cancer and comments on tolerability profiles of available agents.
Switch Maintenance Therapy In Advanced Ovarian Cancer: The ARIEL3 Trial
Ramez Eskander, MD, describes the ARIEL3 study of rucaparib switch maintenance therapy in patients with advanced ovarian cancer.
Frontline Maintenance Therapy in Advanced Ovarian Cancer
Dr Ramez Eskander reviews the options and goals for frontline maintenance therapy in women with advanced ovarian cancer.
Role of Molecular Testing in Advanced Ovarian Cancer
An expert in ovarian cancer reviews best practices for molecular testing in patients with advanced ovarian cancer and the implications of testing results for treatment selections.
Case Presentation: A 64-Year-Old Woman With Ovarian Cancer
Ramez Eskander, MD, discusses the case of a 64-year-old woman diagnosed with ovarian cancer.
Clinical Pearls: EGFR Exon 20 Insertion+ NSCLC Treatment
Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, provide an overview of their major conclusions and clinical pearls for the treatment approach of EGFR Exon 20 Insertion+ NSCLC.
Key Findings from the EXCLAIM Trial
Experts review the toxicity of mobocertinib and further discuss the key findings from the EXCLAIM Trial.
Future Therapeutic Options for Diffuse Large B-Cell Lymphoma
Considering a patient’s relapse and potential response to therapy, Daniel O. Persky, MD, looks forward to the future use of novel therapies in diffuse large B-cell lymphoma.
The GO29365 Trial: Polatuzumab + BR in R/R DLBCL
Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.
Optimal Second-Line Therapy for Diffuse Large B-Cell Lymphoma
Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.
Diffuse Large B-Cell Lymphoma: Frontline Treatment Options
A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.
A Case of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.
Amivantamab and Poziotinib as Treatment Options
Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review amivantamab and poziotinib as other treatment options for EGFR Exon 20 Insertion+ NSCLC.